 33 year old male received teriparatide for 24 months, followed by zoledronic acid annual infusions  31 year old female received teriparatide treatment for 8 months, stopped for 13 months following bowel resection, then re-initiated for a further 12 months ABSTRACT Crohn's disease (CD) often results in abnormalities in bone strength, and ultimately increases the risk of fragility fractures. Up to 55% of patients with CD have bone mineral density (BMD) in the osteopenia range and up to 58% have osteoporosis by BMD.